FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO)

Mechanistic studies revealed that FTO decreased EMG1 expression by demethylating EMG1 and reducing ribosome biosynthesis, thereby promoting bladder cancer cell proliferation, migration, and invasion and repressing tumor growth in vivo. This study has demonstrated the anti-tumor effect of FTO on bladder cancer development, making it a promising therapeutic target.

Our combined theoretical and experimental analyses indicate that both the location and density of m6A modifications critically dictate the extent of reaction inhibition, supporting the use of single-base epigenetic modifications as a versatile tool for chemical system design. This epigenetically regulated platform provides a general framework for dynamic nucleic acid circuits, with broad implications for biosensing, molecular computing, and synthetic biology, advancing the development of epigenetically controlled biochemical systems.

Clinical validation using 20 breast cancer patient tissues demonstrated robust cancer/normal discrimination (AUC = 0.9853) and significant FTO upregulation in triple-negative subtypes (p < 0.001). The modular design establishes a universal framework for epigenetic enzyme detection while enabling dynamic monitoring of tumor epigenetic remodeling.

Pharmacologic inhibition of FTO restores miR-200b/a/429 cluster expression and partially rescues the oncogenic phenotype elicited by FTO overexpression. Collectively, our findings uncover a previously unrecognized FTO-m6A-miR-200b/a/429 axis that propels ESCC progression and highlight FTO as a promising therapeutic target for patients with ESCC.

Furthermore, FTO inhibition led to significant downregulation of key cell cycle regulators at both the transcriptomic and proteomic levels. Collectively, these findings highlight RNA methylation as a critical regulator of DMG tumorigenicity and identify FTO as a promising therapeutic target for this currently incurable disease.

The incorporation of electrodeposited gold nanoparticles on SnO2 spin-coated FTO represents an approach to enhancing the performance and sensitivity of the sensor. This biosensor has potential applications across a range of areas in the field of miRNA detection.

Our findings provide the first comprehensive overview of the transcriptional diversity within the human ALKBH gene family. These results enhance our understanding of the demethylation mechanisms and their dysregulation in cancer.

Experimentally, overexpression of SNORA12 in osteosarcoma cells and primary NK cells significantly upregulated TIGIT at both the mRNA and protein levels, while SNORA12 knockdown in NK92 cells reduced TIGIT expression. This pan-cancer analysis positions SNORA12 as a tumor type-specific prognostic biomarker and reveals its novel role as a positive regulator of TIGIT in osteosarcoma, offering a potential mechanistic link between snoRNA dysregulation and immune evasion.

It induced cell death primarily through ferroptosis, as inhibitors (Ferrostatin-1, Deferoxamine) reversed this effect...Furthermore, in a murine xenograft model, S.C significantly suppressed tumor growth, which was associated with consistent alterations in these ferroptosis-related markers in vivo. Our findings reveal that S.C triggers ferroptosis in EC via the novel FTO-ACSL4 axis, highlighting its potential as a therapeutic agent and identifying the FTO-ACSL4 pathway as a promising target for endometrial cancer treatment.

Consequently, SHEV ORF3 induces metabolic remodeling through a dual "epigenetic-post-transcriptional" mechanism: disrupting m6A homeostasis via FTO suppression and constructing a pathogenic ceRNA network via the ENPP3/miR-181a/KRAS axis. These findings highlight the critical role of non-coding RNAs in driving the virus-induced "pre-pathological state".

This mini-review synthesizes recent mechanistic advances, emphasizes regional and cell-type heterogeneity of YTHDF2 function, and proposes a "dose-target dependency" framework to reconcile its bidirectional effects. We also outline emerging translational strategies aimed at evaluating YTHDF2 as a mechanistic biomarker and a selectively tractable therapeutic target in neurological disease.

Recently, Liao et al. revealed a SAM-independent mechanism wherein adenosylhomocysteinase-adenosine complex modulates fat-mass and obesity-associated protein (FTO), reshapes the mRNA m6A landscape, rewires lipid metabolism, and promotes tumorigenesis, revealing a novel metabolic-epitranscriptomic cancer axis.